journal article·2026-04Open access

Intravesical folate-conjugated hydroxyethyl starch micelles for pH-triggered co-delivery of epirubicin and TLR7 agonist toward synergistic chemoimmunotherapy of bladder cancer

Yuxiu Wang, Haoyang Yuan, Ye Zhang, Yu Zhang, Tian Yin, Haibing He, Xing Tang, Yanjiao Wang, Jingxin Gou, Guofei Li

Abstract

The immunosuppressive tumor microenvironment and poor drug targeting remain major obstacles in bladder cancer (BC) therapy. To address this, a combination strategy integrating chemotherapy and immunotherapy was employed by co-delivering epirubicin (EPI) and the immune modulator imiquimod (IMQ) using a folate-modified nanocarrier. A hydroxyethyl starch-based epirubicin prodrug modified with folic acid (FA-HES-EPI) was first synthesized to improve tumor selectivity. FA-HES-EPI/IMQ micelles were then fabricated via nanoprecipitation by encapsulating IMQ into the hydrophobic core, aiming to achieve synergistic therapeutic efficacy. Folate modification conferred tumor-targeting capability to the micelles and promoted efficient cellular uptake via folate receptor-mediated endocytosis. The acid-sensitive hydrazone bond enabled controlled release of both EPI and IMQ in the acidic tumor microenvironment, thereby enhancing their combined chemo-immunotherapeutic effects. In an orthotopic BC model, FA-HES-EPI/IMQ micelles significantly enhanced drug accumulation at the tumor site, repolarized M2-type tumor-associated macrophages (TAMs) toward the M1 phenotype, remodeled the tumor stroma, and achieved a tumor inhibition rate of 96.7 %, markedly surpassing that of FA-HES-EPI micelles (86.6 %) and free EPI (62.3 %), with negligible systemic toxicity. This pH-responsive co-delivery system represents a promising approach to improve both efficacy and safety in bladder cancer treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Bladder and Urothelial Cancer Treatments · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (34)

Show source-provided references
1. Fluorinated polyethylenimine to enable transmucosal delivery of photosensitizer-conjugated catalase for photodynamic therapy of orthotopic bladder tumors postintravesical instillation10.1002/adfm.201901932 ↗
2. Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review
3. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective10.1038/s41585-022-00578-1 ↗
4. Self-propelled in situ polymerized nanoparticles activating the STING pathway for enhanced bladder cancer immunotherapy
5. Collagen-targeted tumor-specific transepithelial penetration enhancer mediated intravesical chemoimmunotherapy for non-muscle-invasive bladder cancer
6. Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles
7. Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer
8. Targeted uptake of folic acid-functionalized polymeric nanoparticles loading glycoalkaloidic extract in vitro and in vivo assays
9. Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers10.3389/fonc.2024.1438297 ↗
10. The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer10.1002/cac2.12532 ↗
11. Strategies for overcoming immune evasion in bladder cancer10.3390/ijms25063105 ↗
12. Tailor-made autophagy Cascade amplification polymeric nanoparticles for enhanced tumor immunotherapy
13. Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells10.1016/j.apsb.2024.03.010 ↗
14. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy10.3389/fimmu.2023.1227833 ↗
15. Personalized tumor vaccines based on carrier-free double-adjuvant nanoparticles and tumor-associated antigens for enhancing immune responses10.1016/j.cclet.2025.111092 ↗
16. Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of triple-negative breast cancer10.1016/j.mtbio.2025.102012 ↗
17. Improved epirubicin delivery selectivity to bladder cancer achieved by functionalized hydroxyethyl starch-based prodrug
18. The pH of drinking water and its effect on the pH of urine
19. Regulation of drug release performance using mixed doxorubicin-doxorubicin dimer nanoparticles as a pH-triggered drug self-delivery system10.1016/j.jpha.2021.03.001 ↗
20. Measurement of urine pH for epidemiological studies on bladder cancer10.1007/s10654-006-9101-2 ↗
21. Establishing an intravesical doublet chemotherapy clinic for nonmuscle-invasive bladder cancer patients10.1097/UPJ.0000000000000576 ↗
22. Folic acid-doxorubicin-double-functionalized-lipid-core nanocapsules: synthesis, chemical structure elucidation, and cytotoxicity evaluation on ovarian (OVCAR-3) and bladder (T24) cancer cell lines10.1007/s11095-021-02989-y ↗
23. Activating PEG host to enable spatially controlled surface functionalization of nanocarriers for biomedical applications10.1126/sciadv.adu3932 ↗
24. Extending the IMQ model: deep characterization of the human TLR7 response for early drug development10.1007/s10753-024-02127-x ↗
25. IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages10.1038/s41598-023-46237-2 ↗
26. Targeting folate receptor β positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex10.1038/s41392-020-0115-0 ↗
27. Folate receptor β (FRβ) expression in tissue-resident and tumor-associated macrophages associates with and depends on the expression of PU.110.3390/cells9061445 ↗
28. TLR7 in channel catfish (Ictalurus punctatus) is expressed in the endolysosome and is stimulated by synthetic ssRNA analogs, imiquimod, and resiquimod10.1016/j.dci.2024.105197 ↗
29. Hydropenia May accelerates the progression of orthotopic bladder cancer induced by N-methyl-N-nitrosourea by increasing the expression levels of AQP1, AQP3, and AQP410.21037/tau-21-273 ↗
30. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model
31. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma
32. CD4(+) T cells in antitumor immunity10.1016/j.trecan.2024.07.009 ↗
33. Inclusion of fibroblasts and collagen fibrils in the cytologic grading of canine cutaneous mast cell tumors10.1111/vcp.13098 ↗
34. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells